格隆汇2月16日丨北海康成-B(01228.HK)发布公告，2026年2月15日，公司与认购人(即WuXi Biologics HealthCare Venture，为药明生物(02269.HK)的间接全资附属公司)订立认购协议，据此，公司已有条件 同意发行及认购人已有条件同意认购合共8403.36万股认购股份，认购价为每股认购股份2.38港元。认购 事项项下的认购股份相当于本公告日期现有已发行股份数目约16.44%。 认购事项所得款项总额将约为2亿港元，公司根据认购事项应收所得款项净额估计约为1.99亿港元。公 司拟将认购事项所得款项净额用于(i)商业化产品的营运资金及注册维护；(ii)现有产品线的研发开支； 及(iii)结算集团的贸易应付款项。 ...

认购事项所得款项总额将约为2亿港元，及经扣除就认购事项产生的相关开支后，本公司根据认购事项 应收所得款项净额估计约为1.99亿港元。每股认购股份的净发行价为2.37港元。本公司拟将认购事项所 得款项净额用于商业化产品的营运资金及注册维护;现有产品线的研发开支;及结算本集团的贸易应付款 项。 每股认购股份2.38港元的认购价较股份于2026年2月13日(即最后交易日)在联交所所报的收市价每股2.79 港元折让约14.70%。 北海康成-B(01228)发布公告，于2026年2月15日，本公司与认购人订立认购协议，据此，本公司已有条 件同意发行及认购人已有条件同意认购合共8403.36万股认购股份，认购价为每股认购股份2.38港元。 ...

认购事项所得款项总额将约为2亿港元，及经扣除就认购事项产生的相关开支后，本公司根据认购事项 应收所得款项净额估计约为1.99亿港元。每股认购股份的净发行价为2.37港元。本公司拟将认购事项所 得款项净额用于商业化产品的营运资金及注册维护;现有产品线的研发开支;及结算本集团的贸易应付款 项。 每股认购股份2.38港元的认购价较股份于2026年2月13日(即最后交易日)在联交所所报的收市价每股2.79 港元折让约14.70%。 智通财经APP讯，北海康成-B(01228)发布公告，于2026年2月15日，本公司与认购人订立认购协议，据 此，本公司已有条件同意发行及认购人已有条件同意认购合共8403.36万股认购股份，认购价为每股认 购股份2.38港元。 ...

根據一般授權認購新股份 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依賴該等內 容而引致的任何損失承擔任何責任。 本公告或其任何副本概不得直接或間接於美國境內或有關刊發或派發屬違法的任何其他司法權區刊 發或派發。本公告僅作參考用途，並不構成收購、購買或認購本公司任何證券之邀請或要約。 本公告並不構成或組成於美國境內或有關發售屬違法的任何其他司法權區出售證券的任何要約或 招攬購買或認購證券的一部分。本公告所述本公司股份並無亦不會根據1933年美國證券法（經修訂） （「美國證券法」）登記，且不得於美國境內提呈發售或出售，惟根據美國證券法登記規定進行登記者 或獲豁免遵守該等登記規定者除外。本公司無意根據美國證券法登記本公告內所指之任何證券，或 在美國境內進行證券公開發售。 CANbridge Pharmaceuticals Inc. 北海康成製藥有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1228） 根據一般授權認購新股份 於2026年2月15日，本公司與認購人訂立認購協議，據此，本公 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 北海康成製藥有限公司（於開曼群島註冊成立之有限公司） 呈交日期: 2026年2月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01228 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | 0.00001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | 0.00001 | USD | | 50,000 | 本月底法定/註冊 ...

Group 1 - As of February 4, 100 stocks reached a 52-week high, with METROPOLIS CAP (08621), Asia Backup (08290), and Wenling Tooling (01379) leading the high rate at 74.55%, 63.89%, and 57.48% respectively [1] - METROPOLIS CAP closed at 0.048 with a peak of 0.096, while Asia Backup closed at 0.032 with a peak of 0.059, and Wenling Tooling closed at 3.400 with a peak of 6.000 [1] - Other notable stocks that reached new highs include Asia Internet Technology (00679) at 46.23% and Asia Pacific Financial Investment (08193) at 25.45% [1] Group 2 - The 52-week low rankings show that Gaodi Co. (01676) had the largest decline at -45.71%, followed by Xixiang Group (02473) at -23.42% and Jianfa Xingsheng (00731) at -21.51% [3] - Gaodi Co. closed at 0.243 with a low of 0.171, while Xixiang Group closed at 2.370 with a low of 2.060, and Jianfa Xingsheng closed at 0.137 with a low of 0.135 [3] - Other significant declines include Huaxia SOL-R (83460) at -14.34% and Huaxia SOL-U (09460) at -13.97% [3]

Core Insights - The Chinese pharmaceutical industry is set to benefit from a significant policy update with the revised Drug Administration Law Implementation Regulations, which will take effect on May 15, 2026, marking the first comprehensive revision in 23 years [1][2] Group 1: Policy Changes - The revised regulations include over 90% changes from the previous version, emphasizing support for drug innovation and clinical value-oriented research [1] - New measures include a market exclusivity period for pediatric drugs and rare disease medications, with up to 2 years for pediatric drugs and up to 7 years for rare disease treatments, encouraging investment in these areas [1][2] Group 2: Industry Impact - The introduction of a market exclusivity period is expected to incentivize more pharmaceutical companies to invest in the rare disease sector, potentially leading to a reduction in industry competition [2] - The regulations also establish a fast-track review process for drug approvals, aiming to expedite the availability of new and effective treatments for patients [2][3] Group 3: Concerns and Future Outlook - Industry experts express the need for clearer implementation details regarding the applicability of the new exclusivity policies to drugs already approved before the regulations take effect [4] - The overall sentiment is optimistic, with expectations that the revised regulations will significantly enhance the innovation landscape in China's pharmaceutical sector over the next decade [4]

Group 1 - The company North Sea Kang Cheng-B (01228) announced the grant of a total of 6,372,575 stock options to 30 option grantees under its post-IPO stock option plan [1] - Additionally, the company granted a total of 6,372,575 restricted stock units to 28 grantees under its post-IPO restricted stock unit plan [1] - The exercise price for the granted stock options is set at HKD 2.32 per share [1]

Core Viewpoint - Beihai Kangcheng-B (01228) announced the grant of a total of 6,372,575 stock options and 6,372,575 restricted share units to 30 and 28 recipients respectively, under its post-IPO stock option plan and restricted share unit plan, with an exercise price of HKD 2.32 per share [1] Group 1 - The company granted a total of 6,372,575 stock options to 30 option recipients [1] - The company also granted a total of 6,372,575 restricted share units to 28 recipients [1] - The exercise price for the granted stock options is set at HKD 2.32 per share [1]

Core Viewpoint - Beihai Kangcheng-B (01228.HK) announced the granting of a total of 6,372,575 stock options to 30 option grantees and an equal number of restricted share units to 28 restricted share unit grantees as part of its post-IPO stock option plan and restricted share unit plan [1] Group 1 - The company granted a total of 6,372,575 stock options [1] - The stock options were awarded to 30 option grantees [1] - The company also granted 6,372,575 restricted share units to 28 grantees [1]